Trial · NCT03236662
(-)- Epicatechin Becker Muscular Dystrophy
NCT03236662, Phase 2, Completed, Craig McDonald, MD; results first posted 2021-07-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. (-)- Epicatechin Becker Muscular Dystrophy. Trials, record NCT03236662. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03236662
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- (-)- Epicatechin Becker Muscular Dystrophy
- NCT number
- NCT03236662
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 2 participants, actual
- Lead sponsor
- Craig McDonald, MD
- Conditions
- Becker Muscular Dystrophy
- Interventions
- (-)-Epicatechin
- First posted
- 2017-08-02
- Last updated
- 2021-11-24
- Results first posted
- 2021-07-26
- Limitations and caveats
- Small number of subjects analyzed.
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Plasma Follistatin | 48 weeks | blood biomarker concentration |
| Primary | Plasma Myostatin | 48 weeks | blood biomarker concentration |
| Primary | Plasma Nitrates/ SNO | 48 weeks | blood biomarker concentration |
| Primary | Plasma BNP | 48 weeks | blood biomarker concentration |
| Primary | Plasma Creatine Kinase | 48 weeks | blood biomarker concentration |
| Primary | Plasma MMP-9 | 48 weeks | blood biomarker concentration |
| Primary | Plasma TNF-Alpha | 48 weeks | blood biomarker concentration |
| Primary | Plasma TGF-Beta | 48 weeks | blood biomarker concentration |
| Primary | Plasma Follistatin:Myostain Ratio | 48 weeks | Ratio of plasma follistatin to plasma myostatin |
| Secondary | Graded Exercise Test Using a Recumbent Cycle Ergometer | baseline and at 2-minute intervals | blood lactate measured |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Plasma Follistatin | 48 weeks | Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure. | ||
| PRIMARY | Plasma Myostatin | 48 weeks | Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure. | ||
| PRIMARY | Plasma Nitrates/ SNO | 48 weeks | Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure. | ||
| PRIMARY | Plasma BNP | 48 weeks | Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure. | ||
| PRIMARY | Plasma Creatine Kinase | 48 weeks | Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure. | ||
| PRIMARY | Plasma MMP-9 | 48 weeks | Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure. | ||
| PRIMARY | Plasma TNF-Alpha | 48 weeks | Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure. | ||
| PRIMARY | Plasma TGF-Beta | 48 weeks | Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure. | ||
| PRIMARY | Plasma Follistatin:Myostain Ratio | 48 weeks | Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure. | ||
| SECONDARY | Graded Exercise Test Using a Recumbent Cycle Ergometer | baseline and at 2-minute intervals | Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 outcomesResults by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment | 2 | |
| Overall Study | COMPLETED | Treatment | 2 | |
| Overall Study | NOT COMPLETED | Treatment | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment | 0 | 2 |
| Total, other adverse events | Treatment | 0 | 2 |
| Total, serious adverse events | Treatment | 0 | 2 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03236662
GET https://conductscience.org/api/trials/v1/NCT03236662/registered